Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06608901 · ClinicalTrials.gov registry record · Phase 2
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
A Phase 2 study of Sepsis-Induced Hypotension, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT06608901 is a Phase 2 study of Sepsis-Induced Hypotension that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 76 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT06608901, a Phase 2 study of Sepsis-Induced Hypotension, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during the stay in the hospital. The study is looking at several other research questions, including: * How the study drug changes the blood pressure and the amount of intravenous (IV) fluids given to participants with low blood pressure due to sepsis * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG REGN7544
- DRUG PB
Study Locations (20)
New York
- New York University Langone Health Brooklyn Hospital - Brooklyn
- Bellevue Hospital - New York
- New York University Langone Health Tisch-Kimmel Hospital - New York
- Montefiore Medical Center - Weiler Hospital - The Bronx
- Montefiore Medical Center - Moses Campus - The Bronx
Massachusetts
- Massachusetts General Hospital - Boston
- Harvard Medical School - Beth Israel Deaconess Medical Center - Boston
Arizona
- University of Arizona - Tucson
Connecticut
- Yale University - New Haven
Georgia
- Emory University Hospital - Atlanta
Maryland
- Johns Hopkins Hospital - Baltimore
North Carolina
- Atrium Health - Winston-Salem
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06608901
The ClinicalTrials.gov registry entry for NCT06608901 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sepsis-Induced Hypotension appearing as the primary indexed condition, and to 2 interventions - of which REGN7544 is the first listed.
NCT06608901 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT06608901 about?
NCT06608901 is a clinical study titled "A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension". This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sep...
What is the current status of trial NCT06608901?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2025-05-05. Estimated completion is 2026-04-30.
What conditions does trial NCT06608901 study?
This clinical trial studies the following conditions: Sepsis-Induced Hypotension.
What interventions are being tested in trial NCT06608901?
The interventions under investigation include: REGN7544 (DRUG), PB (DRUG).
Who is sponsoring clinical trial NCT06608901?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06608901 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.